Bausch Health vs Google: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Bausch Health and Google side by side

1. 1959Bausch Health

   Milan Panic founds ICN Pharmaceuticals

   Milan Panic, a Yugoslav immigrant to California, founded ICN Pharmaceuticals in 1959 and ran it for four decades. ICN is the predecessor of Valeant Pharmaceuticals and of today's Bausch Health.

2. 1994Bausch Health

   Biovail Corporation International formed in Canada

   On March 29, 1994 Eugene Melnyk consolidated his Canadian drug-delivery business by amalgamating Trimel Corporation with its subsidiary to create Biovail Corporation International, the legal entity that files today as Bausch Health Companies Inc.

3. 1998Google

   Google Founded

   Larry Page and Sergey Brin founded Google after developing PageRank at Stanford University. The search engine ranked web pages by link authority, which made results feel more relevant than portal-era competitors.

4. 2000Google

   AdWords Launch

   Google launched AdWords in 2000 and connected advertising to search intent. Businesses could pay to appear near relevant queries, eventually through auction-based performance advertising.

5. 2003Bausch Health

   ICN renames itself Valeant Pharmaceuticals

   ICN Pharmaceuticals, then based in Costa Mesa, California, took the Valeant Pharmaceuticals name in November 2003 to distance itself from the governance fights of the Panic era.

6. 2004Google

   Google IPO

   Google went public in 2004 using an auction process and priced 19,605,052 shares at $85, raising about $1.67B. The IPO gave the company capital for hiring, data centers, acquisitions, and global expansion.

7. 2005Google

   Android Acquisition

   Google acquired Android in 2005 to secure a role in mobile operating systems before smartphones became the main internet device. Android later gave Google global reach through manufacturers such as Samsung and many others.

8. 2006Google

   YouTube Acquisition

   Google closed the YouTube acquisition in 2006 for stock valued at $1.65B. The deal gave Google a user-generated video platform, creator ecosystem, and advertising surface outside text search before online video had a mature business model.

9. 2008Bausch Health

   J. Michael Pearson becomes chief executive

   Valeant appointed former McKinsey director J. Michael Pearson as chief executive effective February 1, 2008, succeeding Timothy C. Tyson. Pearson replaced internal research spending with debt-funded acquisitions of marketed drugs.

10. 2008Google

    DoubleClick Acquisition

    Google acquired DoubleClick for $3.1B to expand its advertising infrastructure beyond search. The deal strengthened display advertising, ad serving, and publisher relationships. It helped Google build a broader ad-tech stack.

11. 2010Bausch Health

    Biovail and Valeant complete their merger

    The merger of Biovail Corporation and Valeant Pharmaceuticals International closed on September 28, 2010. The combined company kept the Valeant name and Pearson as chief executive but was incorporated in Canada.

12. 2011Bausch Health

    Ortho Dermatologics bought from Johnson and Johnson

    Valeant agreed to acquire the U.S. Ortho Dermatologics assets from Janssen Pharmaceuticals, a Johnson and Johnson company, for about $345M in cash, building the dermatology franchise.

13. 2013Bausch Health

    Bausch + Lomb acquired for $8.7 billion

    Valeant agreed in May 2013 to buy eye-health company Bausch + Lomb from Warburg Pincus for $8.7B in cash, adding contact lenses, lens care, ophthalmic drugs and surgical devices.

14. 2014Google

    DeepMind Acquisition

    Google acquired DeepMind in 2014 to deepen its artificial intelligence research bench. DeepMind later became known for AlphaGo and other breakthroughs in reinforcement learning and scientific AI.

15. 2015Bausch Health

    Salix acquisition closes at about $11.1 billion

    Valeant completed its tender offer for Salix Pharmaceuticals on April 1, 2015 at $173 per share, about $11.1B in equity value and roughly $15.8B including debt, gaining the Xifaxan franchise.

16. 2015Bausch Health

    Drug pricing and Philidor scandal breaks

    Congressional investigators pressed Valeant over 525% and 212% increases on the heart drugs Isuprel and Nitropress, bought in February 2015, and over its undisclosed ties to the Philidor mail-order pharmacy.

17. 2015Google

    Alphabet Restructuring

    Google restructured into Alphabet Inc. In 2015, separating core Google from Other Bets. The move gave investors clearer visibility into Search, YouTube, Android, and Cloud economics while preserving room for Waymo, Verily, Calico, and X.

18. 2016Bausch Health

    Joseph Papa replaces Pearson as chief executive

    Valeant named Perrigo chief executive Joseph C. Papa as chairman and CEO on April 25, 2016, and he took over in early May 2016 with about $30B of debt outstanding.

19. 2017Bausch Health

    Skincare brands and Dendreon sold to cut debt

    Valeant sold the CeraVe, AcneFree and AMBI skincare brands to L'Oreal for about $1.3B and the Dendreon cancer unit to China's Sanpower Group for about $820M, using the proceeds to repay debt.

20. 2018Bausch Health

    Company renamed Bausch Health Companies Inc.

    The name change from Valeant Pharmaceuticals International, Inc. to Bausch Health Companies Inc. was completed on July 13, 2018, and the shares began trading as BHC on the NYSE and TSX on July 16, 2018.

21. 2019Google

    Sundar Pichai Becomes Alphabet CEO

    Sundar Pichai became CEO of Alphabet in 2019 after Larry Page and Sergey Brin stepped back from daily operations. Pichai inherited a company facing cloud competition, antitrust scrutiny, privacy pressure, and rising AI expectations.

22. 2020Bausch Health

    SEC settlement closes the Philidor accounting case

    On July 31, 2020 Bausch Health agreed to pay a $45M civil penalty to settle SEC charges of improper revenue recognition and misleading disclosures tied to Philidor. Former chief executive J. Michael Pearson and two other executives also settled.

23. 2022Bausch Health

    Bausch + Lomb listed on the NYSE and TSX

    Bausch + Lomb common stock began trading under the ticker BLCO on May 6, 2022, and a Bausch Health subsidiary sold 35,000,000 Bausch + Lomb shares in the offering. Bausch Health retained about 88% of the eye-health company and still consolidates it. Thomas J.

24. 2023Google

    Google DeepMind Integration

    Alphabet combined major AI research efforts under Google DeepMind to accelerate frontier model development. The move followed competitive pressure from OpenAI and Microsoft.

25. 2025Bausch Health

    DURECT acquired and record annual revenue reported

    Bausch Health closed the DURECT acquisition on September 11, 2025 for about $63M upfront, completed Solta Medical's Chinese aesthetics distribution purchase on December 1, 2025, and reported FY2025 revenue of $10.266B, up 7%, with net income attributable to Ba…

26. 2025Google

    FY2025 Revenue Tops $402B

    Alphabet reported FY2025 revenue of $402.836B and net income of $132.170B. The milestone showed that Search ads, YouTube, Cloud, and subscriptions kept scaling despite regulatory and AI disruption concerns.

27. 2026Bausch Health

    RED-C trials miss endpoints and trigger a $1.4 billion charge

    In January 2026 the two Phase 3 RED-C trials of amorphous-rifaximin soluble solid dispersion for primary prevention of hepatic encephalopathy missed their primary endpoints.

28. 2026Bausch Health

    Second-quarter 2026 revenue of $2.85 billion and raised guidance

    Bausch Health reported second-quarter 2026 revenue of $2.85B, up 13%, net income attributable to Bausch Health of $258M and adjusted EBITDA of $1.075B, and raised its full-year 2026 revenue, adjusted EBITDA and cash flow guidance.

Acquisitions

Questions about Bausch Health vs Google